TOWA PHARMACEUTICAL CO.,LTD.
4553東和薬品株式会社
Latest half-year results
First half · fiscal year to 2026-03 · filed 2025-11-11For the first half of the fiscal year to 2026-03: Revenue ¥130.5 billion (+5.7% YoY), Ordinary income ¥12 billion (+15.9% YoY), Net income ¥8.2 billion (+25.3% YoY).
| This period | Year on year | |
|---|---|---|
| Revenue | ¥130.5bn | +5.7% |
| Ordinary profit | ¥12.0bn | +15.9% |
| Net profit to owners | ¥8.2bn | +25.3% |
From the securities report on EDINET, which states no forecast. History via /v1/companies/4553/earnings-releases.
Financials
Japan GAAP · consolidated · fiscal year to 2026-03-31- Revenue
- ¥273.7bn
- Net income
- ¥5.3bn
- ROE
- 3.0%
- Equity ratio
- 37.5%
- Dividend / share
- ¥80
- Employees
- 4,923
| Fiscal year | Revenue | Net income | Total assets | Net assets | ROE | EPS | Operating CF |
|---|---|---|---|---|---|---|---|
| 2026-03-31 | ¥273.7bn | ¥5.3bn | ¥475.3bn | ¥178.1bn | 3.0% | ¥106.66 | ¥30.4bn |
| 2025-03-31 | ¥259.6bn | ¥19.0bn | ¥470.8bn | ¥171.6bn | 11.6% | ¥385.71 | ¥23.4bn |
| 2024-03-31 | ¥227.9bn | ¥16.2bn | ¥430.7bn | ¥155.9bn | 11.0% | ¥328.59 | ¥8.2bn |
| 2023-03-31 | ¥208.9bn | ¥2.2bn | ¥371.3bn | ¥136.9bn | 1.6% | ¥44.72 | ¥2.5bn |
| 2022-03-31 | ¥165.6bn | ¥15.9bn | ¥332.1bn | ¥132.2bn | 12.8% | ¥323.36 | ¥22.1bn |
Indicators
Computed by us from filings · fiscal year to 2026-03-31| Metric | Value | Percentile among listed companies |
|---|---|---|
| ROE, % | 3 | 14.7 |
| Ordinary margin | 0.1026 | 69.2 |
| Equity ratio, % | 37.5 | 23.3 |
| Revenue growth | 0.0544 | 52.5 |
| Net income growth | -0.7235 | 9.4 |
| Operating cash flow / assets | 0.064 | 49.8 |
Results wording balance: -0.56. Proprietary text method; it describes the wording only and does not interpret context.
Interest example: if all ¥212.2bn of reported debt repriced by 50 basis points, a year's interest would rise by ¥1.1bn, 3.5% of operating cash flow. Our arithmetic only, not a forecast: fixed-rate debt and hedges are ignored.
Via /v1/companies/4553/indicators. Descriptive figures, not a rating and not investment advice.
From other filings
As the company states themSegments, votes and tender offers
Stated in EDINET filings/v1/companies/4553/segments/v1/companies/4553/votingOwnership changes
All companies →- 2026-07-06
Sumitomo Mitsui DS Asset Management Company, Limited raised holdings in TOWA PHARMACEUTICAL CO.,LTD. (4553) to 6.23% from 5.15%.
- 2026-02-05
Sumitomo Mitsui DS Asset Management Company, Limited disclosed a 5.15% stake in TOWA PHARMACEUTICAL CO.,LTD. (4553), crossing the 5% reporting threshold.
- 2023-06-06
LSV Asset Management raised holdings in TOWA PHARMACEUTICAL CO.,LTD. (4553) to 6.17% from 6.13%.
Trades by 5% holders
From the 60-day trade tables in 5% reports| Holder | Period | Net shares | Net % of shares | Avg. filed price | Range |
|---|---|---|---|---|---|
| LSV Asset Management | 2017-05-26 – 2017-05-31 | -2,900 | −0.02pt | — | — |
Net shares and the average are our calculations. Prices are filed prices as stated by the filer, mostly for off-market trades; they are not market prices. Stock lending, custody transfers and option exercises are excluded from net shares. Every row via /v1/companies/4553/trades.
5% filings
Large shareholding reports on 4553| Filed | Filer | Stake | Change | Stated purpose |
|---|---|---|---|---|
| 2026-07-06 | Sumitomo Mitsui DS Asset Management Company, Limited | 6.23% | +1.08pt | pure investment |
| 2026-02-05 | Sumitomo Mitsui DS Asset Management Company, Limited | 5.15% | — | pure investment |
| 2023-06-06 | LSV Asset Management | 6.17% | +0.04pt | pure investment |
Cross-shareholdings
From the annual report's status of shareholdings- Listed strategic holdings
- 3 issues
- Book value
- ¥582m
- Sold in the year
- — — issues
- Bought in the year
- — — issues
- Mutual, both reports
- 1
- Held by listed cos.
- 2
| Holds | Book value | Shares vs. prior year | Mutual |
|---|---|---|---|
| Mitsubishi UFJ Financial Group, Inc. 8306 | ¥382m | 0.0% | stated |
| Daito Pharmaceutical Co., Ltd. 4577 | ¥174m | +100.0% | both reports |
| Mizuho Financial Group, Inc. 8411 | ¥25m | 0.0% | no |
Held by: Daito Pharmaceutical Co., Ltd. 4577, Astena Holdings Co., Ltd. 8095
Purposes, all holdings and mutual flags via /v1/companies/4553/cross-holdings. Share changes include stock splits.
Major shareholders
As of fiscal year end 2026-03-31| Shareholder | Shares | Ratio |
|---|---|---|
| 株式会社吉田事務所 | 20,100,000 | 40.83% |
| 日本マスタートラスト信託銀行株式会社（信託口） | 3,822,000 | 7.77% |
| US BANK NATIONAL ASSOCIATION JP ACCTS TS | 1,961,000 | 3.98% |
| 株式会社日本カストディ銀行（信託口） | 1,638,000 | 3.33% |
| individual holder | 1,540,000 | 3.13% |
| 株式会社日本カストディ銀行（信託口4） | 1,459,000 | 2.96% |
| individual holder | 1,455,000 | 2.96% |
| 東和薬品社員持株会 | 1,000,000 | 2.03% |
| BNP PARIBAS LUXEMBOURG 2S JASDEC FIM LUXEMBOURG FUNDS UCITS ASSETS | 800,000 | 1.63% |
| 有限会社吉田エステート | 648,000 | 1.32% |
U.S. funds holding 4553
SEC Form N-PORT, reports to 2026-07-3161 U.S. funds held 3,814,567 shares worth $93.1m.
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| Brown Capital Management International Small Company Fund Brown Capital Management Mutual Funds | 1,049,593 | $24.7m | 3.615% | 2026-06-30 |
| VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND VANGUARD STAR FUNDS | 355,182 | $8.9m | 0.001% | 2026-07-31 |
| Avantis International Small Cap Value ETF American Century ETF Trust | 315,500 | $7.8m | 0.039% | 2026-05-31 |
| VANGUARD DEVELOPED MARKETS INDEX FUND VANGUARD TAX-MANAGED FUNDS | 239,562 | $5.6m | 0.002% | 2026-06-30 |
| THE JAPANESE SMALL COMPANY SERIES DFA INVESTMENT TRUST CO | 170,600 | $4.3m | 0.107% | 2026-07-31 |
Up to 25 funds per stock via the API.
Get this as JSON
GET /v1/companies/4553
GET /v1/companies/4553/financials
GET /v1/companies/4553/details
GET /v1/companies/4553/segments
GET /v1/companies/4553/voting
GET /v1/companies/4553/tender-offers
GET /v1/companies/4553/indicators
GET /v1/companies/4553/earnings-releases
GET /v1/events?ticker=4553
GET /v1/companies/4553/trades
GET /v1/companies/4553/cross-holdings
GET /v1/companies/4553/brief